Sivakanth Aloor

Abstract B35: Association between acute leukemias and levels of leptin in blood: A meta-analysis

Background: Leptin, a secretory protein of adipocytes, shown to induce differentiation, proliferation, anti-apoptotic and activation of hematopoietic cells through paracrine interaction in the bone marrow microenvironment. Existing literature provides conflicting evidence as to the association between levels of serum leptin and acute leukemia9s. Purpose: The aim of this study is to conduct a meta-analysis to investigate the association between serum leptin levels and presence of acute leukemia9s. Methods: We searched MEDLINE, CIINHAL and COCHRANE databases for studies reporting serum leptin levels in the peripheral blood and bone marrow with and without acute leukemia9s [Acute lymphoblastic leukemia (ALL)/Acute myleogenous leukemia (AML)]. We included case controls, cohort and cross-sectional studies. We calculated the weighted standardized mean difference (SMD) in serum leptin levels between the acute leukemia9s patients and control groups. Results: Our search strategy yielded 70 articles and we included 10 studies enrolling 354 participants with 176 patients and 178 controls of matched age, sex and BMI (body mass index). We included 108 ALL patients compared with 126 controls and136 AML patients compared with 104 controls. The median age of the ALL and AML group compared to controls was 8.12 yrs. (IQR 7.17 - 26.25) and 42 yrs. (IQR 28.8 – 52.88). The median percentage of females of ALL and AML compared to controls was 45 (IQR 27 – 66) and 52.5 (IQR 47 – 60). The unweighted median serum leptin levels in the ALL and AML groups were 21.2 ng/ml (13.4 – 27.4) and 29.9 ng/ml (5.55 – 55.83) compared to 9.43 ng/ml (6.6 – 17.8) and 31.5 ng/ml (6.43 – 89.77) in the control groups. The SMD9s of having abnormal serum leptin levels of ALL and AML compared to controls was 1.27 (95% CI 0.53 - 2.00) P = 0.001 and – 0.97 (95% CI -1.39 - -0.55) P Conclusion: Increased and decreased serum leptin levels are significantly associated with ALL and AML respectively. Further investigation into the molecular mechanism underlying leptin9s role in acute leukemia9s and its use as an adjunctive screening tool are warranted. Citation Format: Vijaya SenaReddy Dendi, Sivakanth Aloor, Rahul Gadde, Kranthi Kunkalla, Roopesh Reddy Sadashiva Reddy, Jeffrey Gryn. Association between acute leukemias and levels of leptin in blood: A meta-analysis. [abstract]. In: Proceedings of the AACR Special Conference: Metabolism and Cancer; Jun 7-10, 2015; Bellevue, WA. Philadelphia (PA): AACR; Mol Cancer Res 2016;14(1_Suppl):Abstract nr B35.

Abstract B36: Serum adiponectin levels association with acute leukemias: A meta-analysis

Background: Adiponectin, a novel adipokine, secreted by adipocytes in inverse proportion to body fat mass. It is hypothesized that adiponectin exerts a protective role for several type of carcinogenesis, notably those related to obesity including hematological cancers through its anti-apoptotic, anti-inflammatory and anti-angiogenesis properties. Purpose: The aim of this study is to conduct a meta-analysis to investigate the association between serum adiponectin levels and presence of acute leukemia9s. Methods: We searched MEDLINE, CIINHAL and COCHRANE databases for studies reporting serum adiponectin levels in the peripheral blood with and without acute leukemia9s [Acute lymphoblastic leukemia (ALL)/Acute myleogenous leukemia (AML)]. We included case controls, cohort and cross-sectional studies. We calculated the weighted standardized mean difference (SMD) in serum adiponectin levels between the acute leukemia9s patients and control groups. Results: Our search strategy yielded 14 articles and we included 4 studies enrolling 783 participants with 322 patients and 461 controls of matched age, sex and BMI (body mass index). We included 255 ALL patients compared with 240 controls and 67 AML patients compared with 221 controls. The median age of the ALL and AML group compared to controls was 7.39 yrs. (IQR 4.83 – 18.04) and 27 yrs. (IQR 16.03 – 38.08). The median percentage of females of ALL and AML compared to controls was 44.5 (IQR 39.3 – 46.8) and 46.5 (IQR 42.3 – 50.8). The unweighted median serum leptin levels in the ALL and AML groups were 12.65 µg/ml (11.96 – 14.2) and 9.65 µg/ml (6.58 – 12.73) compared to 19.1 µg/ml (17.1 – 20.4) and 27.1 ng/ml (16.03 – 38.08) in the control groups. The SMD of having abnormal serum adiponectin levels of acute leukemia patients compared to controls was -2.77 (95% CI -4.25 - -1.3) P Conclusion: Decreased serum adiponectin levels in acute leukemia9s i.e. in both ALL and AML are significantly associated with acute leukemia9s. Further investigation into the molecular role of serum adiponectin in carcinogenesis is warranted and would perhaps allow for the use of these biomarkers in early diagnosis of acute leukemia. Citation Format: Vijaya SenaReddy Dendi, Sivakanth Aloor, Dinesh Keerty, Jeffrey Gryn, Jeffrey Gryn. Serum adiponectin levels association with acute leukemias: A meta-analysis. [abstract]. In: Proceedings of the AACR Special Conference: Metabolism and Cancer; Jun 7-10, 2015; Bellevue, WA. Philadelphia (PA): AACR; Mol Cancer Res 2016;14(1_Suppl):Abstract nr B36.

TCT-594 Difference in Neointimal Coverage between First Generation versus Second Generation Drug Eluting Stents using Optical Coherence tomography: A Meta-Analysis.

RESULTS L-ISR group had more frequently heterogeneous intima and less frequently homogeneous than E-ISR group (96.0% vs. 77.1% and 4.0% vs. 22.9%, p<0.01). L-ISR group had more frequently TCFA, neovascularization and macrophage findings than E-ISR group (28.0% vs. 2.9%, p<0.01; 54.2% vs. 11.4%, p<0.01; 72.0% vs. 25.7%, p<0.01), whereas PLIA detected in L-ISR group were lower in E-ISR group (6.4% vs. 19.0%, p1⁄40.01). Thrombus and intimal disruption were not significant different between the 2 groups.

TCT-427 Comparison of Neointimal Coverage Patterns between Biodegradable Vascular Stents and Drug Eluting Stents using Optical Coherence tomography: A Meta-Analysis

METHODS The RAI (Registro Absorb Italiano) Registry is an investigator-driven, prospective registry that included consecutive patients treated with Absorb BRS (ABBOTT Vascular, Santa Clara, CA). Small vessel population included patients in which all the treated lesions had a reference vessel diameter (RVD) 2.75 mm at quantitative coronary analysis including patients with very small vessels (RVD 2.25 mm).

738: ASSOCIATION BETWEEN SERUM C-REACTIVE PROTEIN LEVELS AND PULMONARY ARTERIAL HYPERTENSION

Learning Objectives: Accumulating evidence implicates the role of systemic inflammation in the pathogenesis of pulmonary arterial hypertension (PAH). C reactive protein (CRP) is an established marker of inflammation that is active in the physiopathology of the vascular wall. It is hypothesized that the proinflammatory properties of CRP contribute to pulmonary vascular remodeling via modulation of the nuclear factor–kappa B pathway. The association between CRP and PAH is unclear. We conducted a meta-analysis to evaluate the relationship between serum CRP levels and PAH. Methods: We searched MEDLINE, CINAHL and COCHRANE databases for studies reporting serum CRP levels in the PAH and non PAH study population. We included case controls, cohort and cross-sectional studies. We calculated the weighted standardized mean difference (SMD) in serum CRP levels between the PAH and control groups. Results: Our search strategy yielded 124 articles. We included eight studies enrolling 861 participants. PAH was diagnosed either by doppler echocardiography (52%) or right heart catheterization (48%). The median age of the PAH group was 55 yr. (IQR 41 61) vs 48 yr. (IQR 34 56) in the control group. The median body mass index in the PAH group was 25.6 kg/m2 (IQR 24.7–26.4) vs 25.9 kg/m2 (IQR 25.1–27.3) in the control group. The unweighted median serum CRP levels in the PAH group were 6.75 mg/l (IQR 3.912.5) vs 3.15 mg/l (IQR 2 – 6.9) in the control group. The SMD of CRP level was 0.75 (95% CI 0.31 – 1.18) p<0.001 comparing the PAH group vs the control group. Conclusions: An elevated serum CRP level is significantly associated with the presence of PAH. Given the significance of elevated CRP levels in PAH, directing further studies in understanding the role or CRP in the etio-pathogenesis of PAH would help determine newer modalities of therapeutic options and prognostic indicators.